Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial
Authors
Keywords
Rheumatoid arthritis, HbA1c, Type 2 diabetes, Cytokines, Drug therapy, Inflammation, Insulin, Drug metabolism
Journal
PLOS MEDICINE
Volume 16, Issue 9, Pages e1002901
Publisher
Public Library of Science (PLoS)
Online
2019-09-13
DOI
10.1371/journal.pmed.1002901
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis
- (2019) Siri Lillegraven et al. PLoS One
- Efficacy and safety of interleukin-1 antagonists in rheumatoid arthritis: a systematic review and meta-analysis
- (2018) Shekoufeh Nikfar et al. RHEUMATOLOGY INTERNATIONAL
- Novel treatment strategies in rheumatoid arthritis
- (2017) Gerd R Burmester et al. LANCET
- Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis
- (2017) Piero Ruscitti et al. MEDICINE
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Poor clinical response in rheumatoid arthritis is the main risk factor for diabetes development in the short-term: A 1-year, single-centre, longitudinal study
- (2017) Piero Ruscitti et al. PLoS One
- Precision Medicine in Rheumatoid Arthritis
- (2017) James Bluett et al. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
- Multiple benefits of targeting inflammation in the treatment of type 2 diabetes
- (2016) Marc Y. Donath DIABETOLOGIA
- IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone?
- (2016) Roberto Giacomelli et al. Expert Review of Clinical Immunology
- Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1β via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3(NLRP3)-inflammasome activation: a pos
- (2015) P. Ruscitti et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Trends in Insulin Use and Diabetes Control in the U.S.: 1988–1994 and 1999–2012
- (2015) Elizabeth Selvin et al. DIABETES CARE
- Head to Head Comparison of the Formulation and Stability of Concentrated Solutions of HESylated versus PEGylated Anakinra
- (2015) Robert Liebner et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Personalized medicine: Time for one-person trials
- (2015) Nicholas J. Schork NATURE
- Cardiovascular comorbidity in rheumatic diseases
- (2015) Michael T. Nurmohamed et al. Nature Reviews Rheumatology
- Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability
- (2015) Bart V. J. Cuppen et al. RHEUMATOLOGY
- Medication Therapy Management Interventions in Outpatient Settings
- (2015) Meera Viswanathan et al. JAMA Internal Medicine
- The Impact of Traditional Cardiovascular Risk Factors on Cardiovascular Outcomes in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
- (2015) Leena R. Baghdadi et al. PLoS One
- The Comparative Safety of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: A Meta-analysis Update of 44 Trials
- (2014) Tzeyu L. Michaud et al. AMERICAN JOURNAL OF MEDICINE
- The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance
- (2014) P. C. M. van Poppel et al. DIABETES OBESITY & METABOLISM
- Targeting inflammation in the treatment of type 2 diabetes: time to start
- (2014) Marc Y. Donath NATURE REVIEWS DRUG DISCOVERY
- Confounding by Indication Probably Distorts the Relationship between Steroid Use and Cardiovascular Disease in Rheumatoid Arthritis: Results from a Prospective Cohort Study
- (2014) Alper M. van Sijl et al. PLoS One
- Effect of Methotrexate Use and Erythrocyte Methotrexate Polyglutamate on Glycosylated Hemoglobin in Rheumatoid Arthritis
- (2014) Maurits C. F. J. de Rotte et al. Arthritis & Rheumatology
- EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases
- (2013) N Duru et al. ANNALS OF THE RHEUMATIC DISEASES
- Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials
- (2013) Antoinette Moran et al. LANCET
- Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes
- (2012) C. Cavelti-Weder et al. DIABETES CARE
- Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial
- (2012) A. Rissanen et al. DIABETES OBESITY & METABOLISM
- Glucose tolerance, insulin sensitivity and -cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids
- (2011) J. N. Hoes et al. ANNALS OF THE RHEUMATIC DISEASES
- Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: Balance between diabetogenic effects and inflammation reduction
- (2011) Debby den Uyl et al. ARTHRITIS AND RHEUMATISM
- Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study
- (2011) Rieke Alten et al. BMC MUSCULOSKELETAL DISORDERS
- Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-α therapy
- (2010) Miguel A. Gonzalez-Gay et al. Annals of the New York Academy of Sciences
- Stopping Randomized Trials Early for Benefit and Estimation of Treatment EffectsSystematic Review and Meta-regression Analysis
- (2010) Dirk Bassler JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study
- (2009) Mike J. L. Peters et al. ARTHRITIS AND RHEUMATISM
- Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes
- (2009) C. M. Larsen et al. DIABETES CARE
- Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials
- (2009) Kausik K Ray et al. LANCET
- Inhibition of Interleukin-1 by Anakinra Improves Vascular and Left Ventricular Function in Patients With Rheumatoid Arthritis
- (2008) Ignatios Ikonomidis et al. CIRCULATION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now